Back to Screener

Healthcare

Biocartis Group N.V.(BIOGF)

Live Price

Offline

$0.66

-85.33% today

1Y Change

Window

No data

Market Cap
$65.41M
Revenue Growth
+19.1%
EPS Growth
+12.9%
Dividend Yield
0.0%
No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Biocartis Group N.V. (BIOGF) is a Healthcare stock with a market cap of $65.41M. The stock last traded around $0.66. Baseline metrics include revenue growth of +19.1%, EPS growth of +12.9%, a dividend yield of 0.0%. What stands out right now is revenue +19.1%, EPS +12.9%, free cash flow +32.6% with operating margin -81.8% and ROIC -50.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BIOGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+19.1% vs +7.6% peer median

Operating Margin

Below sector median

-81.8% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2024 was reported on Jun 13, 2024, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +19.1% and EPS at +12.9%, with operating margin around -81.8%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

BIOGF

Normalized return

SPY

S&P 500

Excess Return

Relative to SPY

BIOGF Max Drawdown

Trailing 1Y

SPY Max Drawdown

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for BIOGF and SPY.

Calendar-year return history is still loading or unavailable.
BI

Company Overview

Biocartis Group N.V.

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
EV/EBITDA
Price/Sales
0.5
Price/Book

Growth

Revenue
+19.1%
EPS
+12.9%
Free Cash Flow
+32.6%

Profitability

Gross Margin
48.2%
Operating Margin
-81.8%
Net Margin
-113.7%
ROE
203.7%
ROIC
-50.7%

Balance Sheet

Debt/Equity
Current Ratio
1.65

Earnings Reports

📅 Last reportedJun 13, 2024
PeriodB/MEPSEPS ΔRevenueRev Δ
Jun 13, 24
Est
Est
Jun 30, 23
-0.34
Est
29.6B
Est
Feb 23, 23
-0.58
Est
31.2B
Est
Oct 20, 22
-0.46
Est
27625.3B
Est
Apr 19, 22
-0.62
Est
24134.5B
Est
Nov 10, 21
-0.62
Est
24134.5B
Est
May 14, 21
-0.56
Est
21564.0B
Est
Sep 3, 20
-0.56
Est
21564.0B
Est
Mar 5, 20
-0.57
Est
18722.0B
Est
Nov 14, 19
-0.57
Est
18722.0B
Est
Mar 1, 19
Est
Est
Nov 15, 18
Est
Est
Apr 26, 18
Est
Est
Nov 28, 17
Est
Est
Apr 27, 17
Est
Est
Sep 6, 16
Est
Est

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.